XGEVA Improves Metastasis-Free Survival In Castrate-Resistant Prostate Cancer
Cancer Care Cost To Jump by 27 Percent In a Decade, Reaching $158 Billion in 2020
Lilly Suspends Phase III Trial Of Tasisulam in Melanoma
Genomic Health Presents Meta-Analyses of Oncotype DX
In Phase II Study, NKTR-102 Shows Objective Response
Iniparib Plus Chemo Shows Benefit In Phase II Study
ColoPrint Improves Prognosis In Stage II and III Colon Cancer
Test May Identify Predictors For Recurrence Post-Surgery
Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”
